Complaining about what may seem like FDA nit-picking does not minimize problems with clinical trial evidence – that’s the agency’s message for sponsors and advisory committee members who might think the regulator is being overly negative about application data.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?